Ensuring optimal patient outcomes in oncology relies not only on effective therapies but also on systematic approaches to care delivery. Quality Improvement & Safety initiatives focus on enhancing clinical processes, minimizing errors, and standardizing best practices across cancer care settings. By implementing evidence-based protocols, monitoring performance metrics, and conducting regular audits, healthcare teams can identify gaps in care, reduce variability, and improve patient outcomes. Multidisciplinary collaboration among oncologists, nurses, pharmacists, and administrative staff is essential to creating a culture of continuous improvement, where patient safety and treatment effectiveness are prioritized at every stage of care.
The scope of Quality Improvement & Safety extends to patient-centered strategies, including error prevention, risk assessment, and adherence to regulatory standards. Programs often incorporate training, process redesign, and technology integration, such as electronic health records and clinical decision support systems, to enhance accuracy and efficiency. Continuous evaluation of clinical outcomes, patient satisfaction, and adverse events informs refinements in care delivery and policy implementation. By fostering a proactive approach to safety and quality, oncology teams can optimize treatment effectiveness, reduce complications, and enhance the overall patient experience. Integrating these strategies into routine practice ensures that patients receive high-quality, safe, and reliable cancer care, while institutions achieve measurable improvements in performance and outcomes.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Nanomedicine in humans: 30 years of fighting diseases
Thomas J Webster, Northeastern University, United States
Title : Diagnosis and treatment of primary cardiac lymphoma in an immunocompetent 27-year-old man
Moataz Taha Mahmoud Abdelsalam, Madinah Cardiac Center, Saudi Arabia
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Personalized and Precision Medicine (PPM) through the view of biodesign-inspired translational research: An option for clinical oncologists, caregivers, and consumers to realize the potential of genomics-informed care to secure human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation